Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIERE: Enzalutamide in mCRPC
NCT02288936Phase 2Completed
- Sponsor
- SOGUG
- Start
- Feb 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOGUG. Started Feb 2015; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02288936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288936.